[Corrections] Correction to Lancet Oncol 2023; 24: 1002–17

May, 05, 2024 | Select Oncology Journal Articles

Leal T, Kotecha R, Ramlau R, et al. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023; 24: 1002–17—In this Article, a footnote was added to table 3, which reads “In the immune checkpoint inhibitor subgroup, one additional patient had an adverse event (atrial fibrillation) of unknown grade and two additional patients had respiratory tract infection adverse events of unknown grade.” The appendix was also updated.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy